Text/HTML

Annual Meeting.gif

The RADARS System annual meeting encourages prescription drug abuse experts, representatives from the pharmaceutical industry, medical professionals, and federal regulatory agencies to discuss current trends in prescription drug abuse research and to develop strategies to ensure the safe and proper use of prescription medications.

 

Meeting Summaries:

 

·          2008: From Signals to Interventions

 

·          2007: New Developments in Prescription Drug Abuse Research

 

 

 

 

 

 

 

 



Save the Date!

2009 RADARS System Annual Scientific Meeting

Thursday, April 23, 2009  ¦  Bethesda, Maryland

2008 RADARS System Annual Scientific Meeting:

From Signals to Interventions

Thursday, May 1, 2008  ¦  Bethesda, Maryland

 

The 2008 annual scientific meeting focused on new developments in prescription drug abuse research and interventions. In addition, an overview of newly developed signal detection systems and annualized 2007 RADARS System data was presented. Experts in public health interventions and in prescription drug abuse and interventions served as speakers at the meeting and the following presentations were given at the meeting.

 

·          Dr. Jennifer Sabel from the Washington State Department of Health presented Prescription Opiate Deaths in Washington State and Potential Solutions

 

·          Patrizia Carrieri from the French National Institute from Health and Medical Research presented The Importance of Measuring Drug Related Harms and Benefits of Treatment in Post-Marketing Surveillance: Lessons from Buprenorphine

 

·          Commander John Burke from the National Association of Drug Diversion Investigators presented Law Enforcement and the Pharmaceutical Industry-Collaboration for Success

 

·          Dr. Michael Arthur of the University of Washington presented Using Community Monitoring to Promote Healthy Development: The Communities that Care Prevention System 

 

·          Dr. Curtis Wright of Star Pharmaceuticals presented Getting to Intervention: Lessons Learned from Abusable Drugs for Pharmaceutical Risk Assessment, Management and Intervention

 

Privacy Statement  |  Terms Of Use
(c) 2006 RMPDC